Last reviewed · How we verify
MK-0954A
MK-0954A is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.
MK-0954A is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).
At a glance
| Generic name | MK-0954A |
|---|---|
| Sponsor | Organon and Co |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor (neurokinin-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Pain Management |
| Phase | Phase 3 |
Mechanism of action
The drug works by binding to and blocking NK1 receptors, which are involved in pain transmission and emetic (nausea/vomiting) pathways. By antagonizing these receptors, MK-0954A reduces pain signaling and chemotherapy-induced nausea and vomiting (CINV). This mechanism has been explored for both pain management and antiemetic applications.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
Common side effects
- Headache
- Dizziness
- Fatigue
Key clinical trials
- MK0954A-264 Filter Study (0954A-264)(COMPLETED) (PHASE3)
- HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED) (PHASE3)
- Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323) (PHASE3)
- Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314) (PHASE4)
- A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327) (PHASE3)
- A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3) (PHASE4)
- MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352) (PHASE3)
- A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-0954A CI brief — competitive landscape report
- MK-0954A updates RSS · CI watch RSS
- Organon and Co portfolio CI